Radiation Therapy in 5 Sessions or Less
Complete your cancer treatment in 5 sessions or less
If you’ve been diagnosed with breast, prostate or lung cancer and radiation therapy is part of your treatment, you should know about important technology advance that can dramatically reduce your treatment time to just 5 days or less—with results that are as good or better than conventional radiation therapy that takes a lot longer.
Called accelerated hypofractionated radiation therapy (or precision stereotactic body radiation therapy), this breakthrough advanced treatment safely delivers higher doses of radiation during each treatment session. As a result, you can complete treatment in 5 or fewer daily sessions—compared to 25 to 45 sessions over 5 to 9 weeks with conventional radiation therapy.
This highly precise, sophisticated technology is now available at the Nuvance Cancer Institute at Norwalk Hospital as part of our partnership with the renowned Memorial Sloan Kettering (MSK) Cancer Center—giving you close-to-home access to today’s most advanced and effective therapies.
How accelerated hypofractionated radiation therapy works
The benefits of accelerated hypofractionated radiation therapy
The notable benefits of this short-course approach to radiation therapy include:
Who’s a candidate for accelerated hypofractionated radiation therapy?
A growing number of patients with breast, prostate and lung cancer are being treated with accelerated hypofractionated radiation therapy. In fact, it’s now considered a standard of care for treating appropriately selected patients with these types of cancer.
If you have breast, prostate or lung cancer and radiation therapy is part of your treatment, you will be carefully evaluated by our MSK-led radiation oncology team to determine if this treatment approach is right for you.
Why choose the Nuvance Cancer Institute at Norwalk Hospital for accelerated hypofractionated radiation therapy?
Memorial Sloan Kettering is a pioneer in treating cancer with radiation and was among the first cancer centers in the nation to use hypofractionated radiation therapy to treat certain types of cancer. Through our innovative collaboration with Memorial Sloan Kettering, MSK physicians and other staff are now available here at the Nuvance Cancer Institute at Norwalk Hospital—for your convenience, peace of mind, and the best-possible outcome.
Learn more about accelerated hypofractionated radiation therapy
Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial [e-pub ahead of print]. Lancet. https://doi.org/10.1016/S0140-6736(19)31131-6, Accessed July 1, 2019.
MJ Zelefsky, A Pinitpatcharalert, M Kollmeier… - European urology …, 2019
Katz AJ, Kang J. Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol. 2014;4:301.
Davis J, Sharma S, Shumway R, Perry D, Bydder S, Simpson CK, et al. Stereotactic body radiotherapy for clinically localized prostate cancer: toxicity and biochemical disease-free outcomes from a multi-institutional patient registry. Cureus [Internet]. 2015. Available from: http://www.cureus.com/articles/3466-stereotactic-body-radiotherapy-for-clinically-localized-prostate-cancer-toxicity-and-biochemical-disease-free-outcomes-from-a-multi-institutional-patient-registry.
Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92(5):971–7.
Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97(5):976–85.